Targacept to Report Second Quarter 2008 Financial Results on August 5, 2008
Winston-Salem, North Carolina
July 29, 2008
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. Eastern Daylight Time on Tuesday, August 5, 2008 following the after-market release of its financial results for the second quarter ended June 30, 2008. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call, during which they will discuss Targacept’s financial results and provide an update on the company's product development programs and business activities.
A live webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on Targacept’s website for at least two weeks following the call.
The conference call may be accessed by dialing 800-322-2803 for domestic participants and 617-614-4925 for international callers (reference passcode 23370280). A replay of the conference call may be accessed at least through August 19, 2008 by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers (reference passcode 59054894).
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept’s product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer’s disease, cognitive dysfunction in schizophrenia, pain and depression, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at www.targacept.com.
Contacts:
Alan Musso, VP and CFO
Targacept, Inc.
Tel: (336) 480-2186
Email: alan.musso@targacept.com
Michelle Linn
Linnden Communications
Tel: (508) 362-3087
Email: michelle@linndencom.com
Back to Newsroom